Opportunities for reducing the use of non-human primates in the development of monoclonal antibodies – a workshop report
Owner/Developer: National Center for Replacement, Refinement & Reduction of Animals in Research (NC3Rs)
The workshop provided a forum for open and frank discussion about the possibility of replacing or reducing primate use in the development of monoclonal antibodies (MAbs). There was general consensus that there are opportunities for reduction by the use of transgenic rodents and/or surrogate antibodies and replacement by the use of in vitro data and humans as the toxicology species. There are major challenges if these alternatives are to be realised in practice and accepted by regulatory bodies.
|Audience:||Scientists - Regulators - Industry|
|User access:||Open access|
|Purpose:||Animal welfare - Method development|
|Technology/Tools:||Alternative test methods (in vitro) - Animal testing (in vivo)|
Did you find what you were looking for?Yes, I found it! No, I did not!
Thanks for your feedback! Please note that we cannot respond unless you supply your email address.
What are you looking for?
Please give us your feedback so we can improve the information on the page. Thank you in advance for your help. Please add your email address if you would like a reply.Please contact us by email if you have any questions.